New PARP On The Block: BioMarin Starts Phase III, Could Prove To Be Best-In-Class
This article was originally published in Pharmaceutical Approvals Monthly
Class’s comeback gets more fuel at AACR/NCI/EORTC targeted therapies meeting. Evidence indicates BioMarin may have the most powerful PARP inhibitor, though AstraZeneca and Tesaro are slightly further in development.
You may also be interested in...
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.